TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed Price. Currency in USD
17.01
-0.64 (-3.63%)
At close: 4:01PM EST

17.15 +0.14 (0.82%)
After hours: 7:23PM EST

Stock chart is not supported by your current browser
Previous Close17.65
Open17.71
Bid0.00 x 900
Ask0.00 x 1000
Day's Range17.00 - 17.94
52 Week Range16.35 - 25.96
Volume13,648,472
Avg. Volume11,314,876
Market Cap42.429B
Beta (3Y Monthly)0.99
PE Ratio (TTM)N/A
EPS (TTM)-10.87
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-11-27
1y Target Est22.94
Trade prices are not sourced from all markets
  • Teva Reports Positive Top-Line Data for Migraine Candidate
    Zacks10 hours ago

    Teva Reports Positive Top-Line Data for Migraine Candidate

    Teva (TEVA) announces positive top-line data from the phase IIIb study on fremanezumab for the preventive treatment of migraine in adult patients.

  • Alkermes, Biogen Submit NDA to FDA for Multiple Sclerosis Drug
    Zacks11 hours ago

    Alkermes, Biogen Submit NDA to FDA for Multiple Sclerosis Drug

    Alkermes (ALKS) and Biogen submit an NDA to the FDA for diroximel fumarate (BIIB098), being developed for the treatment of relapsing forms of MS.

  • 3 Value Stocks to Absolutely Love During This Correction
    Motley Fool14 hours ago

    3 Value Stocks to Absolutely Love During This Correction

    Given time, these brand-name stocks could pay big dividends to investors.

  • Business Wireyesterday

    Teva Announces Positive Topline Phase IIIb Results with Fremanezumab in Adults with Migraine Who Did Not Respond to Multiple Classes of Preventive Treatments

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced positive topline results from the Phase IIIb FOCUS study that evaluated the efficacy and safety of fremanezumab for the preventive treatment of migraine in adult patients who previously experienced inadequate responses to two to four classes of preventive treatments. In the study of 838 patients, including those who suffer from either chronic or episodic migraine, patients treated with fremanezumab experienced highly significant reduction in the monthly average number of migraine days versus placebo (-0.6 days) over the 12 week assessment period, for both monthly (-4.1 days, p

  • Business Wire4 days ago

    Celltrion and Teva Announce FDA Approval of HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications

    Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has approved HERZUMA® (t

  • Warren Buffett's 10 Big Stock Losers
    Investopedia7 days ago

    Warren Buffett's 10 Big Stock Losers

  • InvestorPlace5 days ago

    Should Warren Buffett — And You — Buy More TEVA Stock Right Now?

    The last few years for drug-maker Teva Pharmaceuticals (NASDAQ:TEVA) haven’t exactly been that wonderful. TEVA stock has plunged on a series of mishaps and issues. In fact, TEVA has fallen enough that America’s favorite value investor, Warren Buffett, has taken a huge interest in the stock over the last few quarters.

  • Reuters5 days ago

    Teva Pharm to move headquarters to Tel Aviv

    Israel-based Teva Pharmaceutical Industries said on Thursday it was moving its headquarters to Tel Aviv as part of a global restructuring. Teva, the world's largest generic drugmaker, said its new base will replace a number of sites located in the area of Petah Tikva, a city just outside of Tel Aviv -- Israel's commercial capital. Teva has been restructuring itself over the past year to deal with its massive debt, including lay-offs, site closings and the combining of divisions.

  • Zacks7 days ago

    Teva (TEVA) Stock Poised to Record Big Gains in 2019?

    Teva's (TEVA) shares outperform the industry in 2018 so far after a massive drop in 2017. Let's see how it is poised for the next year.

  • InvestorPlace8 days ago

    3 Big Stock Charts for Tuesday: Micron Technology, Fortive and Morgan Stanley

    Headed into Tuesday’s session, stock charts of Micron Technology (NASDAQ:MU), Fortive (NYSE:FTV) and Morgan Stanley (NYSE:MS) are worth a closer look. Three weeks ago we pointed out how Micron Technology shares were trending lower, framed by a well-defined falling trading range. It may well be en route to the lower edge of that trading range again, but if it is, there’s a much bigger technical support line that will have to snap first.

  • Zacks7 days ago

    Generic Drugmakers Down on Allegations of Price Fixing

    An article in The Washington Post levels charges of price fixing against several generic drugmakers, driving their shares down.

  • Generic-drug stocks slammed by report of expanded price-fixing probe
    MarketWatch8 days ago

    Generic-drug stocks slammed by report of expanded price-fixing probe

    Shares of generic drug makers fell sharply Monday, after a Washington Post report that an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing across the industry.

  • ACCESSWIRE8 days ago

    Today's Research Reports on Trending Tickers: Teva Pharmaceutical and Innovate Biopharmaceuticals

    NEW YORK, NY / ACCESSWIRE / December 11, 2018 / Several generic drug stocks were falling into the red on Monday, including Teva Pharmaceuticals, after Wall Street learned that a Washington Post report said an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing across the industry. Shares of Innovate Biopharmaceuticals were soaring despite any news from the company. Innovate Biopharmaceuticals, Inc.

  • Why Teva Pharmaceutical Industries, Tivity Health, and Marine Products Slumped Today
    Motley Fool8 days ago

    Why Teva Pharmaceutical Industries, Tivity Health, and Marine Products Slumped Today

    Learn what held these companies' stocks back on a choppy day for the market.

  • MarketWatch8 days ago

    Generic drug makers stocks fall sharply after report of expanded price-fixing probe

    Shares of generic drug makers fell sharply Monday, after a Washington Post report that an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing. The case now involves at least 16 companies and 300 drugs, the report said, citing Joseph Nielsen, an assistant attorney general and antitrust investigator in Connecticut, who has been a leader in the probe. Nielsen is quoted as saying, "this is most likely the largest cartel in the history of the United States." The victims were consumers and taxpayers, who have been carrying the high cost of overcharges on common antiboitics, blood-pressure medications, arthritis treatments, anxiety pills and more, said the report. Teva Pharmaceuticals Industries Ltd. ADRs fell 5.7% on the news. Mylan NV was down 4.6%, and Dr. Reddy Labs Ltd was down 3%. Abbott Labs was down 1.4% and Pfizer Inc. was down 1.6%. The S&P 500 was down 1.8% and the Dow Jones Industrial Average was down about 2%.

  • Zacks Small Cap Research8 days ago

    ATRS: Xyosted & Epi Pen Available for Sale

    The last week of November was a good one for Antares Pharma, Inc. (ATRS) with both Epi Pen and Xyosted now commercially available. Teva Pharmaceuticals (TEVA) announced on November 27th that the recently approved AB-rated generic Epinephrine Pen is now available in the United States. For the remainder of 2018, only the Epi Pen 0.3 mg version will be available in limited quantities with additional supply of the 0.3 mg version and Epi Pen Jr (0.15 mg) to be available in 2019.

  • Is Teva Pharmaceutical Industries Limited (TEVA) A Good Stock To Buy?
    Insider Monkey9 days ago

    Is Teva Pharmaceutical Industries Limited (TEVA) A Good Stock To Buy?

    We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]

  • Roche's Kadcyla Halves Death Risk in Breast Cancer Study
    Zacks12 days ago

    Roche's Kadcyla Halves Death Risk in Breast Cancer Study

    Roche (RHHBY) announces detailed data from a late-stage study on Kadcyla in early breast cancer patients. Kadcyla reduces risk of disease recurrence by 50% compared to Herceptin.

  • Bausch’s Ultra Multifocal Contact Lenses Get FDA Approval
    Market Realist12 days ago

    Bausch’s Ultra Multifocal Contact Lenses Get FDA Approval

    On December 5, Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies, announced that the US FDA provided 510(K) clearance for its Ultra multifocal contact lenses for use in patients with astigmatism. The Ultra multifocal toric lens will be the first of its kind available for standard use.

  • Mylan Expands Recall of Valsartan to All Unexpired Lots
    Zacks13 days ago

    Mylan Expands Recall of Valsartan to All Unexpired Lots

    Mylan (MYL) expands recall of batches of blood pressure medicine in the United States to include all Valsartan-based products within expiry.

  • Generics and Biosimilar Business Is Major Growth Driver for Teva
    Market Realist14 days ago

    Generics and Biosimilar Business Is Major Growth Driver for Teva

    How Is Teva Pharmaceutical Positioned in 2018? On November 29, Celltrion issued a press release announcing FDA approval of Truxima, a biosimilar version of Roche Holdings’ (RHHBY) Rituxan in three indications. On October 6, 2016, Teva Pharmaceutical (TEVA) issued a press release announcing a partnership with Celltrion for the commercialization of biosimilar versions of Rituxan and Herceptin in the US and Canada.

  • Roche Announces Positive Data on Venclexta/Venclyxto at ASH
    Zacks14 days ago

    Roche Announces Positive Data on Venclexta/Venclyxto at ASH

    Roche (RHHBY) announces new Venclexta/Venclyxto data that demonstrate deep responses in two of the most common types of leukaemia.

  • Reuters14 days ago

    U.S. justices wrestle with patent arguments for anti-nausea drug

    U.S. Supreme Court justices on Tuesday grappled with a Swiss pharmaceutical company's effort to salvage a patent behind its lucrative anti-nausea drug in a case that could make it easier to cancel key patents, especially among smaller drugmakers. The justices asked tough questions of both sides during an hour of oral arguments in an appeal by Helsinn Healthcare S.A. of a lower court's decision to invalidate its patent on Aloxi, which paved the way for Israel-based Teva Pharmaceutical Industries to launch a generic version of the drug in March. Aloxi is used to prevent nausea and vomiting in patients receiving chemotherapy.

  • Austedo Is on Solid Growth Trajectory in 2018
    Market Realist14 days ago

    Austedo Is on Solid Growth Trajectory in 2018

    How Is Teva Pharmaceutical Positioned in 2018? On April 3, 2017, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of Austedo for chorea associated with Huntington’s disease. According to Teva Pharmaceutical’s third-quarter earnings conference call, almost 40,000 people in the US suffer from Huntington’s disease.

  • Ajovy Is a New Growth Driver for Teva Pharmaceutical
    Market Realist14 days ago

    Ajovy Is a New Growth Driver for Teva Pharmaceutical

    How Is Teva Pharmaceutical Positioned in 2018? On September 14, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of Ajovy, a humanized monoclonal antibody and anti-calcitonin gene-related peptide (or CGRP) therapy for migraine prevention indication. Teva Pharmaceutical expects to secure regulatory approval from the European Commission (or EC) for Ajovy in migraine prevention indication in H1 2019.